- Home
- SKT vs GRFS Comparison
SKT vs GRFS Comparison
Compare SKT & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKT | GRFS |
|---|---|---|
| Founded | 1981 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.9B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | SKT | GRFS |
|---|---|---|
| Price | $41.93 | $7.58 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $37.17 | $10.15 |
| AVG Volume (30 Days) | ★ 749.7K | 647.2K |
| Earning Date | 04-30-2026 | 07-28-2022 |
| Dividend Yield | ★ 3.18% | 1.80% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.37 | $4.49 |
| Revenue Next Year | $3.90 | $6.42 |
| P/E Ratio | $171.29 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.24 | $6.96 |
| 52 Week High | $42.05 | $11.14 |
Technical Indicators
Market Signals| Indicator | SKT | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 63.80 | 55.96 |
| Support Level | $38.75 | $7.64 |
| Resistance Level | $42.05 | $7.73 |
| Average True Range (ATR) | 0.73 | 0.16 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 90.86 | 68.62 |
Price Performance
Historical ComparisonAbout SKT Tanger Inc.
Tanger Inc is an owner and operator of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.